Provided by Tiger Trade Technology Pte. Ltd.

Alterity Therapeutics Limited

4.67
+0.22004.94%
Post-market: 4.670.00000.00%17:16 EDT
Volume:10.59K
Turnover:48.72K
Market Cap:84.65M
PE:-7.06
High:4.72
Open:4.60
Low:4.51
Close:4.45
52wk High:5.89
52wk Low:2.66
Shares:18.13M
Float Shares:14.40M
Volume Ratio:0.47
T/O Rate:0.07%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.6613
EPS(LYR):-0.7470
ROE:-47.02%
ROA:-32.54%
PB:2.18
PE(LYR):-6.25

Loading ...

Craig-Hallum bullish on Alterity Therapeutics, initiates with a Buy

TIPRANKS
·
Aug 11

Alterity Therapeutics to Present at the 46th Annual Canaccord Genuity Growth Conference

GlobeNewswire
·
Aug 06

Alterity Therapeutics Releases Appendix 4C – Q4 FY26 Quarterly Cash Flow Report & Corporate Update

GlobeNewswire
·
Jul 30

Alterity Therapeutics to Participate in the Virtual BTIG Biotechnology Conference 2026

GlobeNewswire
·
Jul 21

Alterity Therapeutics initiated with a Buy at JonesResearch

TIPRANKS
·
Jun 30

Alterity Therapeutics assumed with a Buy at Ladenburg

TIPRANKS
·
Jun 16

Top Premarket Decliners

MT Newswires Live
·
Jun 11

Alterity Therapeutics achieves alignment with FDA on program for ATH434 in MSA

TIPRANKS
·
Jun 09

Alterity Therapeutics Achieves Alignment with U.S. FDA on Pivotal Phase 3 Program for ATH434 in Multiple System Atrophy

GlobeNewswire
·
Jun 09

Alterity Therapeutics publishes quantitative susceptibility mapping MRI data

TIPRANKS
·
May 11

Alterity Therapeutics to Deliver Presentations at Multiple Medical Conferences in May 2026

GlobeNewswire
·
May 07

Alterity Therapeutics Releases Appendix 4C – Q3 FY26 Quarterly Cash Flow Report & Corporate Update

GlobeNewswire
·
Apr 30

Alterity Therapeutics Presents New Analysis of ATH434 Phase 2 Trial Data in Late Breaking Science Session of the American Academy of Neurology

GlobeNewswire
·
Apr 22

Alterity Therapeutics appoints Ann Cunningham to board as independent director

Reuters
·
Apr 17

Alterity Therapeutics to Host Virtual KOL Event to Share New Insights on ATH434 for the Treatment of Multiple System Atrophy

GlobeNewswire
·
Apr 15

Alterity Therapeutics appoints Daniel Claasen as chief medical advisor

TIPRANKS
·
Mar 04

Alterity Therapeutics Appoints Daniel O. Claassen, M.D., M.S., as Chief Medical Advisor

GlobeNewswire
·
Mar 04

Alterity Therapeutics recognizes MSA Awareness Month

TIPRANKS
·
Mar 02

Alterity Therapeutics Recognizes Multiple System Atrophy (MSA) Awareness Month in March and the Urgent Need for Disease-Modifying Treatments

GlobeNewswire
·
Mar 02